TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00279812

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50ug selenium enriched yeast
Description: Selenomethionine supplement (50ug/d Se) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100ug selenium enriched yeast
Description: Selenomethionine supplement (100ug/d Se) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200ug selenium enriched yeast
Description: Selenomethionine supplement (200ug/d Se) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control onion
Description: 3 meals per week containing un-enriched onion (4ug/d) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched onion
Description: 3 meals per week containing un-enriched onion (50ug/d) for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement for 12 weeks
Study: NCT04313491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Relaxation yoga exercises, yoga breathing, yoga sound and imagery practices
Study: NCT00007644

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical prostatectomy
Description: Surgical removal of the prostate
Study: NCT02438345

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCr5

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PRO 140
Description: Humanized monoclonal antibody to CCr5
Study: NCT02631265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 1
Description: Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 2
Description: Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise 3
Description: Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
Study: NCT03477058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 3308 cosmetic product for topical use
Description: Application on the entire body at least once a day over two weeks
Study: NCT03684694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral capsule.
Study: NCT02291926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human umbilical cord mesenchymal stem cells
Description: A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
Study: NCT03826823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HSG cannula
Description: a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
Study: NCT04340804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kcal labelling
Description: Real-time kcal counter synchronised with the food amount changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kcal labelling
Description: Real-time kcal counter synchronised with the food amount changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE labelling
Description: Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACE labelling
Description: Real-time PACE counter (as minutes needed to walk to burn off the calories) synchronised to the food amount changes
Study: NCT02469662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexel Total Elbow
Description: Nexel Total Elbow used in primary or revision total elbow arthroplasty

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexel Total Elbow
Description: Nexel Total Elbow used in primary or revision total elbow arthroplasty
Study: NCT02589873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Diabetes Prevention Program
Description: Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Diabetes Prevention Program
Description: Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
Study: NCT02694562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40um Embozene TANDEM Microspheres
Description: 40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
Study: NCT02736942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TME
Description: Laparoscopic Total Mesorectal Excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TaTME
Description: Transanal Total Mesorectal Excision
Study: NCT02023892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Study: NCT04303780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 21 day cycles
Study: NCT03259386

Intervention type: DEVICE
Intervention: Microelectrode array
Description: Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
Study: NCT00200044

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Gatekeeper Reflux Repair System
Description: The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score \>15.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gatekeeper Reflux Repair System
Description: The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score \>15.
Study: NCT00141778

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once a day
Study: NCT02023892

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04050267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - air
Description: Breathing air with 21 % oxygen, no nitrous oxide.
Study: NCT00387647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine given subcutaneously as outlined in treatment arm.
Study: NCT04030247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plant Sterol
Description: Patients will receive a plant sterol supplement to take twice daily from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
Study: NCT02408809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Smoking Cessation Discussion
Description: This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
Study: NCT02176850

Intervention type: DRUG
Intervention: Micardis®
Study: NCT04408482

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation
Description: Cannulation of biliary duct by sphincterotome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary cannulation
Description: Cannulation of biliary duct by sphincterotome
Study: NCT02408809

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Orthopaedic Related Smoking Cessation Discussion
Description: The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
Study: NCT00892359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
Study: NCT04039412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid regimen
Description: two-step (dual-quadruple) treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reverse hybrid regimen
Description: one-step two-phase (quadruple-dual) treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin quadruple regimen
Description: non-Clarithromycin non-Bismuth quadruple therapy
Study: NCT01330485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Regulation Training
Description: The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Common Factor Control Condition
Description: The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
Study: NCT00999557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost ophthalmic solution
Description: Applied topically
Study: NCT05053841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT00999557

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Applied topically
Study: NCT02197806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201
Description: 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201
Description: 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201
Description: 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584
Description: 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584
Description: 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584
Description: 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-199201 Vehicle
Description: 1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
Study: NCT00141778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Taken orally, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Taken orally, once a day
Study: NCT03338725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy model
Description: Patients who are being monitored by a clinical pharmacy model

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical pharmacy model
Description: Patients who are being monitored by a clinical pharmacy model
Study: NCT03423940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional communication training
Description: During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional communication training
Description: During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior).
Study: NCT02629666

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERS and/or Self-management Strategies
Study: NCT03601559

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei Lpc-37
Description: Live probiotic bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert placebo matched for taste and appearance
Study: NCT02210832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best practices
Study: NCT02558205

Intervention type: RADIATION
Intervention: CT Liver Perfusion
Description: Imaging study of liver using injection of Iodine contrast agent done using CT imaging

Intervention type: RADIATION
Intervention: PET/CT of liver
Description: PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
Study: NCT00552591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week risk reduction program, managed by a Heart Health Educator
Description: The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
Study: NCT00540566

Intervention type: DEVICE
Intervention: Optical Biopsy imaging
Description: Optical Biopsy imaging
Study: NCT01084772

Intervention type: OTHER
Group type: OTHER
Intervention: VISIONAIRE Total Knee Arthroplasty
Description: TKA will be performed with VISIONAIRE instrumentation, depending on randomization assignment.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Total Knee Arthroplasty
Description: TKA will be performed with standard instrumentation, depending on randomization assignment.
Study: NCT02442037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC group
Description: Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10\^6/kg) ,once every week，a total of three times.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group(Normal saline)
Description: Normal saline in same volume as MSCs are transplanted to patients.
Study: NCT03167008

Intervention type: DIAGNOSTIC_TEST
Intervention: semen sample
Description: -Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)

Intervention type: DIAGNOSTIC_TEST
Intervention: semen sample
Description: -Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: blood samples will be taken \&the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
Study: NCT01867307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: open label
Study: NCT04439825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Neurotoxin
Description: glabella, forehead lines and/or lateral canthal lines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (preservative free)
Study: NCT00234676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin ®
Description: Premarin ® 0.625 mg per day orally
Study: NCT03357237

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: medical device
Description: patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical device
Description: patients will be assigned, following an external randomization, to two groups:~* Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~* Control or reference group: treatment regimen with oral rehydration solution and placebo